Zachary BrennanSenior EditorBiogen quietly announced at a conference in Spain today that a manuscript of the Phase III results for the company’s controversial Alzheimer’s drug Aduhelm has finally been published in a tiny journal with a conflicted chief editor, almost a year after the drug won its accelerated approval. The manuscript was published Wednesday in...